Article Sidebar

PDF
Date Published: 03/05/2024
Abstract Views: 60
Views PDF: 113
DOI: https://doi.org/10.56535/jmpm.v49.776
Issue
Vol. 49 (2024): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ - SỐ ĐẶC BIỆT 5/2024
Section
CDHA
How to Cite
Nguyễn, H. N., Nguyễn, K. L., Ngô, V. Đ., Ngô, V. Đ., & Mai, H. T. (2024). HETEROGENEITY INDEX AND QUANTITATIVE VALUES OF PRIMARY TUMOR ON PET/CT IN RESECTABLE NON-SMALL CELL LUNG CANCER PATIENTS. Journal of Military Pharmaco-medicine, 49, 26-34. https://doi.org/10.56535/jmpm.v49.776

HETEROGENEITY INDEX AND QUANTITATIVE VALUES OF PRIMARY TUMOR ON PET/CT IN RESECTABLE NON-SMALL CELL LUNG CANCER PATIENTS

Hải Nguyễn Nguyễn1, , Nguyễn Kim Lưu, Ngô Văn Đàn, Ngô Vĩnh Điệp, Huy Thông Mai
1 103 Military Hospital

Main Article Content

Abstract

Objective: Investigating the heterogeneity and the quantitative values of primary tumor in resectable non-small cell lung cancer (NSCLC) patients.


Subjects and Methods: A retrospective study was conducted on 49 NSCLC patients undergoing PET/CT. Heterogeneity index (HI) and quantitative values on PET/CT images were measured. Data was entered and processed using SPSS 26.0 software.


Results: The majority of patients were male, with adenocarcinoma subtype histology. There was a statistically significant difference in dmax, SUVmax, SUR, MTV, and TLG of the tumor primary with T stages, p <0.05; no statistically significant difference was found in SUVmean and HI between T stages. The heterogeneity index had a strong positive correlation with SUVmax and SUR, with a moderate positive correlation with SUVmean, MTV, TLG, and dmax, p <0.01.


Conclusion: The heterogeneity index of Primary tumor in NSCLC correlates closely with the quantitative values of PET/CT imaging.





 


 


 

 


Article Details

Keywords

Heterogeneity index, Quantitative values, PET/CT, Lung cancer

References

1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer journal for clinicians. 2021; 71(3):209-249.
2. Goldstraw P, et al. The iaslc lung cancer staging project: Proposals for revision of the tnm stage groupings in the forthcoming (eighth) edition of the tnm classification for lung cancer. J Thorac Oncol. 2016; 11(1):39-51.
3. Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2):328-354.
4. Van Der Gucht A, et al. Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in patients with Neurofibromatosis Type-1. PLoS One. 2016; 11(3):e0151809.
5. Shin S, et al. Prognostic value of tumor-to-blood standardized uptake ratio in patients with resectable non-small-cell lung cancer. Nucl Med Mol Imaging. 2017; 51(3):233-239.
6. Shang J, et al. Predictive value of metabolic parameters derived from preoperative 18F-FDG positron emission tomography/computed tomography for brain metastases in patients with surgically resected non-small cell lung cancer. Quant Imaging Med Surg. 2023; 13(12):8545-8556.
7. Wen W, et al. Prognostic value of MTV and TLG of 18F-FDG PET in patients with stage I and II non-small-cell lung cancer: A meta-analysis. Contrast Media Mol Imaging. 2021:7528971.
8. Wang D, et al. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma. Medicine (Baltimore). 2021; 100(35): e27100.
9. Zito Marino F, et al. Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications. Int J Med Sci. 2019; 16(7):981-989.